Core Insights - Perrigo reported $1.04 billion in revenue for the quarter ended September 2025, reflecting a year-over-year decline of 4.1% and an EPS of $0.80, slightly down from $0.81 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $1.1 billion, resulting in a surprise of -4.84%, while the EPS exceeded expectations by 6.67% against a consensus estimate of $0.75 [1] Financial Performance Metrics - Net Sales for Consumer Self-Care International (CSCI) were $398 million, below the average estimate of $432.27 million, marking a year-over-year decline of 4.4% [4] - Net Sales for Consumer Self-Care Americas (CSCA) reached $646 million, compared to the estimated $664.1 million, representing a decrease of 3.8% year-over-year [4] - Adjusted Gross Profit for CSCI was reported at $199 million, falling short of the estimated $228.07 million [4] - Adjusted Gross Profit for CSCA was $218 million, slightly above the average estimate of $217.28 million [4] Stock Performance - Perrigo's shares have returned -6.9% over the past month, contrasting with a +1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers across various molecules, dosage forms, and value tiers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [3] Upcoming Events - The President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on September 3rd, 2025 [1]

Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [3] Upcoming Events - The President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 12th at 9:00 AM EDT [1]

Core Viewpoint - Perrigo Company plc is set to release its second quarter 2025 financial results on August 6, 2025, and will host a conference call to discuss these results [1] Company Overview - Perrigo Company plc is a leading provider of Consumer Self-Care Products with over a century of experience in delivering high-quality health and wellness solutions primarily in North America and Europe [3] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering accessible self-care solutions that do not require a prescription [3] Business Model - Perrigo's business model is characterized by its complementary businesses, where cash-generative store brand private label offerings support investments in leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [4]

Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers across various molecules, dosage forms, and value tiers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Solpadeine® [3] Upcoming Events - President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference on June 10 at 9 AM ET, which will be conducted virtually [1]

Core Points - Perrigo Company plc plans to release its first quarter 2025 financial results on May 7, 2025, at 8:30 A.M. (EST) [1] - The earnings conference call will be accessible via webcast and phone, with a replay available from May 7 to May 14, 2025 [2] - Perrigo is a leading provider of Consumer Self-Care Products and OTC health solutions aimed at enhancing individual well-being [3]